| Antibody Name | Target Antigen | Product Type | Isotype | Sponsors | Indication | Trial Status | Year |
|---|---|---|---|---|---|---|---|
| 5G1.1 | Complement (C5) | Humanised | IgG | Alexion Pharm Inc | Rheumatoid Arthritis | I/II | |
| 5G1.1 | Complement (C5) | Humanised | IgG | Alexion Pharm Inc | SLE | I/II | |
| 5G1.1 | Complement (C5) | Humanised | IgG | Alexion Pharm Inc | Nephritis | I/II | |
| 5G1.1-SC | Complement (C5) | Humanised | ScFv | Alexion Pharm Inc | Cardiopulmanory Bypass | I/II | |
| 5G1.1-SC | Complement (C5) | Humanised | ScFv | Alexion Pharm Inc | Myocardial Infarction | I/II | |
| 5G1.1-SC | Complement (C5) | Humanised | ScFv | Alexion Pharm Inc | Angioplasty | I/II | |
| ABX-CBL | CBL | Human | Abgenix Inc | GvHD | II | ||
| ABX-CBL | CD147 | Murine | IgG | Abgenix Inc | Allograft rejection | II | |
| ABX-IL8 | IL-8 | Human | IgG2 | Abgenix Inc. | Psoriasis | I/II | |
| AD-159 | gp120 | Humanised | Tanox Biosystems/ | HIV | I/II | ||
| AD-439 | gp120 | Humanised | Tanox Biosystems | HIV | I/II | ||
| Antegren | VLA-4 | Humanised | IgG | Athena/Elan | Multiple Sclerosis | II | |
| Anti-CD11a | CD11a | Humanised | IgG1 | Genentech Inc/Xoma | Psoriasis | II | |
| Anti-CD18 | CD18 | Humanised | Fab'2 | Genentech Inc | Myocardial infarction | II | |
| Anti-LFA1 | CD18 | Murine | Fab'2 | Pasteur-Merieux/Immunotech | Allograft rejection | III | |
| Anti-VEGF | VEGF | Humanised | IgG1 | Genentech Inc | Cancer (general | II | |
| Antova | CD40L | Humanised | IgG | Biogen | Allograft rejection | I/II | |
| Antova | CD40L | Humanised | IgG | Biogen | SLE | II | |
| BEC2 | anti-Id | Murine | IgG | ImClone Sys/Merk KGaA | Lung | III | |
| BIRR-1 | ICAM-1 | Murine | IgG2a | Boehringer Pharm | Stroke | III | |
| BTI-322 | CD2 | Rat | IgG | Medimmune Inc | GvHD | II | |
| C225 | EGFR | Chimeric | IgG | Imclone Sys | Head+Neck | III | |
| CAT-152 | TGF-beta 2 | Human | Cambridge Ab Tech | Glaucoma Surgery | I/II | ||
| CDP571 | TNF-alpha | Humanised | IgG4 | Celltech | Crohn's | II | |
| CDP571 | TNF-alpha | Humanised | IgG4 | Celltech | Rheumatoid Arthritis | II | |
| CDP850 | E-selectin | Humanised | Celltech | Psoriasis | I | ||
| Corsevin M | Fact VII | Chimeric | Centocor | Anticoagulant | I | ||
| D2E7 | TNF-alpha | Human | CAT/BASF | Rheumatoid Arthritis | I/II | ||
| Herceptin | Her2/neu | Humanised | IgG1 | Genentech | Metastatic Breast | FDA approval | 1998 |
| HNK20 | F gp | Murine | IgA | Peptide Therap Gp | RSV | III | |
| Hu23F2G | CD11/18 | Humanised | ICOS Pharm Inc | Multiple Sclerosis | II | ||
| Hu23F2G | CD11/18 | Humanised | IgG | ICOS Pharm Inc | Stroke | III | |
| IC14 | CD14 | ? | ICOS Pharm Inc | Toxic shock | I | ||
| ICM3 | ICAM-3 | Humanised | ICOS Pharm Inc | Psoriasis | I/II | ||
| IDEC-114 | CD80 | Primatised | IDEC Pharm/Mitsubishi | Psoriasis | I | ||
| IDEC-131 | CD40L | Humanised | IDEC Pharm/Eisai | SLE | I | ||
| IDEC-131 | CD40L | Humanised | IDEC Pharm/Eisai | Multiple Sclerosis | I | ||
| IDEC-151 | CD4 | Primatised | IgG1 | IDEC Pharm/GlaxoSmithKline | Rheumatoid Arthritis | II | |
| IDEC-152 | CD23 | Primatised | IDEC Pharm | Asthma/Allergy | ? | ||
| Infliximab | TNF-alpha | Chimeric | IgG1 | Centocor | Rheumatoid Arthritis | BLA | |
| Infliximab | TNF-alpha | Chimeric | IgG1 | Centocor | Crohn's | FDA approval | 1998 |
| LDP-01 | beta2-integrin | Humanised | IgG | Millennium Inc (LeukoSite Inc.) | Stroke | II | |
| LDP-01 | beta2-integrin | Humanised | IgG | Millennium Inc (LeukoSite Inc.) | Allograft rejection | II | |
| LDP-02 | alpha4beta7 | Humanised | Millennium Inc (LeukoSite Inc.) | Ulcerative Colitis | II | ||
| LDP-03 / Campath1H | CD52 | Humanised | IgG1 | Millennium Inc (LeukoSite Inc.) | CLL | BLA | |
| Lym-1 | HLA DR | Chimeric | Techiclone Corp. | NHL | III | ||
| LympoCide | CD22 | Humanised | Immonomedics | NHL | I/II | ||
| MAK-195F | TNF alpha | Murine | Fab'2 | Knoll Pharm, BASF | Toxic shock | III | |
| MDX-33 | CD64 (FcR) | Human | Medarex/Centeon | Autoimmune haematogical disorders | II | ||
| MDX-CD4 | CD4 | Human | IgG | Medarex/Eisai/Genmab | Rheumatoid Arthritis | I | |
| MEDI-500 | TCR alpha beta | Murine | IgM | Medimmune Inc | GvHD | III | |
| MEDI-507 | CD2 | Humanised | Medimmune Inc | Psoriasis | II | ||
| MEDI-507 | CD2 | Humanised | Medimmune Inc | GvHD | II | ||
| OKT4A | CD4 | Humanised | IgG | Ortho Biotech | Allograft rejection | II | |
| OrthoClone OKT4A | CD4 | Humanised | IgG | Ortho Biotech | Autoimmune disease | II | |
| Orthoclone/anti-CD3 OKT3 | CD3 | Murine | mIgG2a | Ortho Biotech | Allograft rejection | FDA approval | 1986 |
| Ostavir | Hep B | Human | Protein Design Lab/Novartis | Hep B | II | ||
| OvaRex | CA 125 | Murine | Altarex | Ovarian | II | ||
| Panorex 17-1A | EpCAM | Murine | IgG2a | GlaxoSmithKline / Centocor | Colorectal | German approval | 1995 |
| PRO542 | gp120 | Humanised | Progenics / Genzyme transgenics | HIV | I/II | ||
| Protovir | CMV | Humanised | IgG1 | Prot Design Lab/Novartis | CMV | III | |
| RepPro/Abciximab | gpIIbIIIa | Chimeric | Fab | Centocor/Lilly | Complications of coronary angioplasty | FDA approval | 1994 |
| rhuMab-E25 | IgE | Humanised | IgG1 | Genentech/Norvartis/Tanox Biosystems | Asthma/Allergy | III | |
| Rituxan | CD20 | Chimeric | IgG1 | IDEC Pharm | NHL | FDA approval | 1997 |
| SB-240563 | IL5 | Humanised | GlaxoSmithKline | Asthma/Allergy | II | ||
| SB-240683 | IL-4 | Humanised | GlaxoSmithKline | Asthma/Allergy | II | ||
| SCH55700 | IL-5 | Humanised | Celltech/Schering | Asthma/Allergy | I | ||
| Simulect | CD25 | Chimeric | IgG1 | Novartis Pharm | Allograft rejection | FDA approval | 1998 |
| SMART a-CD3 | CD3 | Humanised | Protein Design Lab | Autoimmune disease | I | ||
| SMART a-CD3 | CD3 | Humanised | Protein Design Lab | Allograft rejection | I/II | ||
| SMART a-CD3 | CD3 | Humanised | IgG | Protein Design Lab | Psoriasis | I/II | |
| SMART M195 | CD33 | Humanised | IgG | Protein Design Lab / Kanebo | AML | III | |
| SMART 1D10 | HLA | ? | Protein Design Lab | NHL | I | ||
| Synagis | F gp | Humanised | IgG1 | MedImmune | RSV (Paediatric) | FDA approval | 1998 |
| Vitaxin | VNRintegrin | Humanised | Ixsys | Sarcoma | II | ||
| Zenapax | CD25 | Humanised | IgG1 | Protein Design Lab/Hoffman-La Roche | Allograft rejection | FDA approval | 1997 |
A list of the company websites is available as another web page.
The inclusion of any antibody, or company name, in the table above does not imply any endorsement of them, the products, or the services offered. The list has been compiled in order to persue academic questions related to the sequences of the antibody molecules in human clinical trials.
This table has been compiled from a number of public sources including web sites of pharmaceutical and biotechnology companies as well as the information provided in market analysts reports. It is likely that there are errors including transcriptional and typographical errors. Do not rely on this information without checking other sources first. I would be most pleased to hear of any updates or corrections to this information. Please email me at my address below.
For the Therapeutic Antibody Human Homology Project I would like to cross reference the above information to the protein sequences of the antibodies [if they exist in public sources such as GenEMBL or in the scientific literature or published patents]. If you can provide any of the information in the questions below this will be of use.
If you are able to help then please do send an email to me at my address mrc7@cam.ac.uk
Remember to bookmark this site before leaving.
Requests for this page since the counter was last reset.
Mike Clark